Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Sold by Harbour Capital Advisors LLC

Harbour Capital Advisors LLC lowered its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 0.7% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 6,242 shares of the pharmaceutical company’s stock after selling 44 shares during the period. Harbour Capital Advisors LLC’s holdings in Vertex Pharmaceuticals were worth $2,541,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Forza Wealth Management LLC increased its position in Vertex Pharmaceuticals by 5.9% in the 4th quarter. Forza Wealth Management LLC now owns 881 shares of the pharmaceutical company’s stock valued at $355,000 after acquiring an additional 49 shares during the period. Cooper Financial Group increased its holdings in shares of Vertex Pharmaceuticals by 16.1% in the fourth quarter. Cooper Financial Group now owns 4,682 shares of the pharmaceutical company’s stock valued at $1,885,000 after purchasing an additional 651 shares during the period. Wedmont Private Capital raised its stake in shares of Vertex Pharmaceuticals by 11.8% during the fourth quarter. Wedmont Private Capital now owns 3,633 shares of the pharmaceutical company’s stock worth $1,488,000 after purchasing an additional 384 shares during the last quarter. Asset Allocation & Management Company LLC acquired a new stake in shares of Vertex Pharmaceuticals during the fourth quarter worth $228,000. Finally, Czech National Bank grew its position in Vertex Pharmaceuticals by 6.2% in the 4th quarter. Czech National Bank now owns 55,838 shares of the pharmaceutical company’s stock valued at $22,486,000 after buying an additional 3,260 shares during the last quarter. 90.96% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

VRTX has been the subject of several recent analyst reports. Wells Fargo & Company reduced their target price on shares of Vertex Pharmaceuticals from $555.00 to $460.00 and set an “overweight” rating for the company in a research note on Friday. Needham & Company LLC reaffirmed a “hold” rating on shares of Vertex Pharmaceuticals in a report on Friday, December 20th. Jefferies Financial Group raised Vertex Pharmaceuticals from a “hold” rating to a “buy” rating and increased their target price for the stock from $500.00 to $550.00 in a research note on Monday, December 9th. JPMorgan Chase & Co. reduced their target price on Vertex Pharmaceuticals from $503.00 to $500.00 and set an “overweight” rating for the company in a report on Monday, December 23rd. Finally, BMO Capital Markets lowered their price target on shares of Vertex Pharmaceuticals from $566.00 to $520.00 and set an “outperform” rating on the stock in a research note on Friday, December 20th. Three analysts have rated the stock with a sell rating, ten have issued a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Vertex Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $490.38.

Vertex Pharmaceuticals Stock Up 0.9 %

Vertex Pharmaceuticals stock traded up $3.62 during trading on Monday, reaching $413.18. 1,082,014 shares of the company’s stock were exchanged, compared to its average volume of 1,438,186. The company’s 50-day moving average is $448.88 and its two-hundred day moving average is $467.95. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.20 and a current ratio of 2.47. Vertex Pharmaceuticals Incorporated has a 52-week low of $377.85 and a 52-week high of $519.88. The firm has a market cap of $106.41 billion, a price-to-earnings ratio of -207.63 and a beta of 0.40.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings results on Monday, November 4th. The pharmaceutical company reported $4.38 earnings per share for the quarter, beating analysts’ consensus estimates of $3.61 by $0.77. Vertex Pharmaceuticals had a negative net margin of 4.52% and a negative return on equity of 1.91%. The business had revenue of $2.77 billion during the quarter, compared to analyst estimates of $2.69 billion. During the same period last year, the business earned $3.67 EPS. The business’s revenue was up 11.6% on a year-over-year basis. On average, analysts predict that Vertex Pharmaceuticals Incorporated will post -1.83 earnings per share for the current year.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.